Reimagining the future of African brain health: Perspectives for basic research on the pathogenesis of cryptococcal meningitis.

R Dangarembizi
Author Information
  1. R Dangarembizi: Division of Physiological Sciences, Department of Human Biology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Abstract

Cryptococcal meningitis is a fatal opportunistic infection of the brain and a leading cause of neurological damage and death in immunocompromised individuals. This neglected fungal disease of the brain is a huge burden on the health systems of developing countries, especially in Sub-Saharan Africa, where up to 25% of people living with HIV/AIDS succumb to it. Cryptococcal fungal cells have a predilection for the brain and they are capable of traversing the blood brain barrier and invade the brain where they cause infection, inflammation and a disruption of normal brain function. A robust host neuroimmune response is critical for pathogen clearance and survival, and a good understanding of the mechanisms underlying its development in the host is critical for the development of effective treatments. However, past basic research studies have been focussed on the characteristics of the fungus and its effect on the peripheral immune system; with little attention paid to how it interacts with brain immune cells. This mini review briefly discusses the paucity of basic research data on the neuroimmune response to cryptococcal infection, raises pertinent questions on how the brain cells respond to the fungal infection, and thereafter discusses models, techniques and advanced technologies that could be useful for carrying out high-throughput research on the pathogenesis of cryptococcal meningitis.

Keywords

References

  1. J Infect Dis. 2013 Jun 15;207(12):1817-28 [PMID: 23493728]
  2. Infect Immun. 2004 Sep;72(9):4985-95 [PMID: 15321990]
  3. BMC Med Genomics. 2021 Apr 16;14(1):108 [PMID: 33863324]
  4. J Fungi (Basel). 2017 Aug 28;3(3): [PMID: 29371564]
  5. J Neuroimmunol. 1995 Oct;62(1):43-52 [PMID: 7499491]
  6. Infect Immun. 2009 Dec;77(12):5389-99 [PMID: 19752036]
  7. Infect Immun. 1997 Feb;65(2):557-63 [PMID: 9009313]
  8. Neurosci Bull. 2020 May;36(5):530-544 [PMID: 31828740]
  9. Virulence. 2012 Mar-Apr;3(2):173-81 [PMID: 22460646]
  10. Adv Exp Med Biol. 2012;946:253-75 [PMID: 21948373]
  11. Exp Ther Med. 2017 Dec;14(6):5243-5250 [PMID: 29285049]
  12. J Infect Dis. 2014 Jan 1;209(1):74-82 [PMID: 23945372]
  13. Lancet Infect Dis. 2019 Apr;19(4):e143-e147 [PMID: 30344084]
  14. J Infect Dis. 1998 Jan;177(1):260-3 [PMID: 9419203]
  15. J Immunol. 2008 Mar 15;180(6):4067-74 [PMID: 18322216]
  16. Curr Infect Dis Rep. 2007 Nov;9(6):457-64 [PMID: 17999881]
  17. Mem Inst Oswaldo Cruz. 2018;113(7):e180111 [PMID: 29668824]
  18. Open Forum Infect Dis. 2021 Feb 05;8(4):ofab066 [PMID: 33937434]
  19. J Immunol. 2001 Apr 1;166(7):4620-6 [PMID: 11254720]
  20. Clin Infect Dis. 2006 Oct 15;43(8):1069-73 [PMID: 16983622]
  21. PLoS Pathog. 2015 Apr 08;11(4):e1004754 [PMID: 25853653]
  22. mBio. 2017 Jan 31;8(1): [PMID: 28143979]
  23. Nat Immunol. 2017 Feb;18(2):132-141 [PMID: 28092376]
  24. Infect Immun. 2005 Aug;73(8):4922-33 [PMID: 16041006]
  25. J Immunol. 2005 Feb 1;174(3):1746-50 [PMID: 15661940]
  26. PLoS Negl Trop Dis. 2019 Jul 22;13(7):e0007566 [PMID: 31329596]
  27. Antiviral Res. 2017 Mar;139:59-68 [PMID: 28025085]
  28. J Infect Dis. 2010 Sep 15;202(6):962-70 [PMID: 20677939]
  29. Genome Biol. 2017 Oct 27;18(1):200 [PMID: 29073931]
  30. J Neurosci Res. 1999 Jun 15;56(6):644-51 [PMID: 10374819]
  31. J Fungi (Basel). 2018 Mar 07;4(1): [PMID: 29518906]
  32. J Infect Dis. 2005 Sep 1;192(5):888-92 [PMID: 16088839]
  33. J Fungi (Basel). 2017;3(4): [PMID: 29333430]
  34. Microbiol Immunol. 2007;51(11):1115-9 [PMID: 18037789]
  35. Lab Invest. 1995 Dec;73(6):871-9 [PMID: 8558850]
  36. Brain Behav Immun. 2020 Jan;83:180-191 [PMID: 31604143]
  37. Mycopathologia. 2010 Nov;170(5):315-30 [PMID: 20552280]
  38. J Immunol. 2012 Oct 15;189(8):4060-8 [PMID: 22984078]
  39. J Comp Neurol. 2011 Feb 15;519(3):480-505 [PMID: 21192080]
  40. PLoS Med. 2012;9(9):e1001316 [PMID: 23055838]
  41. Infect Immun. 2004 Sep;72(9):5373-82 [PMID: 15322035]
  42. PLoS Negl Trop Dis. 2017 Jun 29;11(6):e0005575 [PMID: 28662028]
  43. Med Mycol. 1998 Aug;36(4):189-97 [PMID: 9776834]
  44. mSphere. 2019 Aug 7;4(4): [PMID: 31391283]
  45. BMJ Open. 2018 Jul 30;8(7):e020654 [PMID: 30061436]
  46. BMC Genomics. 2015 Feb 05;16:34 [PMID: 25649146]
  47. Mycoses. 2017 Jul;60(7):447-453 [PMID: 28338245]
  48. Postgrad Med J. 2001 Dec;77(914):769-73 [PMID: 11723315]
  49. J Fungi (Basel). 2017 Dec 25;4(1): [PMID: 29371497]
  50. Clin Infect Dis. 2007 Jul 1;45(1):76-80 [PMID: 17554704]
  51. Cell Tissue Res. 2018 Apr;372(1):41-50 [PMID: 29435650]
  52. Am J Respir Cell Mol Biol. 1997 Dec;17(6):733-9 [PMID: 9409560]
  53. J Fungi (Basel). 2018 Mar 30;4(2): [PMID: 29601494]
  54. An Acad Bras Cienc. 2015 Aug;87(2 Suppl):1293-309 [PMID: 26247147]
  55. Cytokine. 2011 Dec;56(3):739-48 [PMID: 22004922]
  56. J Neuroimmunol. 2008 Nov 15;204(1-2):66-74 [PMID: 18786731]
  57. Clin Infect Dis. 2000 Jan;30(1):47-54 [PMID: 10619732]
  58. mBio. 2015 Nov 17;6(6):e01765-15 [PMID: 26578681]
  59. Curr Med Chem. 2004 Jan;11(2):253-66 [PMID: 14754421]
  60. BMC Genomics. 2017 Sep 6;18(1):696 [PMID: 28874114]
  61. Infect Immun. 2009 Sep;77(9):3749-58 [PMID: 19564388]
  62. Int J Surg Pathol. 2009 Dec;17(6):444-8 [PMID: 18611927]
  63. Mycopathologia. 1983 Jun 20;82(3):179-84 [PMID: 6350885]
  64. Rev Infect Dis. 1991 Nov-Dec;13(6):1163-9 [PMID: 1775849]
  65. AIDS. 2009 Jun 1;23(9):1182-3 [PMID: 19451796]
  66. PLoS Pathog. 2017 Feb 16;13(2):e1006033 [PMID: 28207848]
  67. Int J Mol Med. 2017 Jun;39(6):1525-1532 [PMID: 28440395]
  68. BMC Genomics. 2020 Jul 14;21(1):482 [PMID: 32664861]
  69. J Exp Med. 1994 Jul 1;180(1):365-9 [PMID: 8006595]
  70. PLoS One. 2017 Mar 10;12(3):e0173866 [PMID: 28282442]
  71. Am J Respir Cell Mol Biol. 1995 Oct;13(4):487-95 [PMID: 7546779]
  72. J Neurosci. 2015 Feb 11;35(6):2417-22 [PMID: 25673836]
  73. Neuroscience. 2015 Oct 1;305:86-98 [PMID: 26254240]
  74. Cell Commun Signal. 2014 Sep 10;12:51 [PMID: 25201772]
  75. J Neuroinflammation. 2013 Jun 05;10:71 [PMID: 23738865]
  76. Nat Immunol. 2020 Jul;21(7):802-815 [PMID: 32541832]
  77. Genome Res. 2015 May;25(5):679-89 [PMID: 25858952]
  78. Mycopathologia. 2012 Jun;173(5-6):387-94 [PMID: 22143898]
  79. AIDS. 2009 Mar 27;23(6):701-6 [PMID: 19279443]
  80. Emerg Infect Dis. 2005 Nov;11(11):1686-92 [PMID: 16318719]
  81. Lancet Infect Dis. 2017 Aug;17(8):873-881 [PMID: 28483415]
  82. Front Immunol. 2018 Apr 30;9:855 [PMID: 29760698]
  83. Eur J Immunol. 2005 Mar;35(3):870-8 [PMID: 15714580]
  84. Infect Immun. 2016 Sep 19;84(10):3047-62 [PMID: 27481252]
  85. eNeuro. 2019 Aug 26;6(4): [PMID: 31371457]
  86. Clin Infect Dis. 2009 Sep 1;49(5):702-9 [PMID: 19613840]
  87. Semin Neurol. 2014 Feb;34(1):47-60 [PMID: 24715488]
  88. PLoS One. 2012;7(10):e47853 [PMID: 23110112]
  89. Infect Dis Clin North Am. 2016 Mar;30(1):179-206 [PMID: 26897067]
  90. Ann Indian Acad Neurol. 2010 Apr;13(2):136-8 [PMID: 20814499]
  91. Tohoku J Exp Med. 2010 Sep;222(1):33-7 [PMID: 20814175]
  92. Fish Shellfish Immunol. 2008 Oct;25(4):341-50 [PMID: 18640057]
  93. Am J Pathol. 2005 Feb;166(2):421-32 [PMID: 15681826]
  94. Infect Immun. 1998 Oct;66(10):4994-5000 [PMID: 9746609]
  95. J Neuroinflammation. 2005 Nov 15;2:25 [PMID: 16285888]
  96. Brain Behav Immun. 2018 Feb;68:211-223 [PMID: 29074357]
  97. PLoS One. 2017 Jan 20;12(1):e0169347 [PMID: 28107361]
  98. AIDS. 2009 Feb 20;23(4):525-30 [PMID: 19182676]
  99. Dis Model Mech. 2019 Jun 17;12(6): [PMID: 31101657]
  100. Semin Respir Crit Care Med. 2011 Dec;32(6):727-34 [PMID: 22167400]
  101. Infect Immun. 2009 Oct;77(10):4345-55 [PMID: 19620339]
  102. PLoS One. 2013 Jun 28;8(6):e67311 [PMID: 23840659]

Grants

  1. MR/N006364/2/Medical Research Council
  2. MR/V033417/1/Medical Research Council

Word Cloud

Created with Highcharts 10.0.0braininfectionresearchmeningitisfungalcellsbasiccryptococcalCryptococcalcausehostneuroimmuneresponsecriticaldevelopmentimmunediscussespathogenesisfatalopportunisticleadingneurologicaldamagedeathimmunocompromisedindividualsneglecteddiseasehugeburdenhealthsystemsdevelopingcountriesespeciallySub-SaharanAfrica25%peoplelivingHIV/AIDSsuccumbpredilectioncapabletraversingbloodbarrierinvadeinflammationdisruptionnormalfunctionrobustpathogenclearancesurvivalgoodunderstandingmechanismsunderlyingeffectivetreatmentsHoweverpaststudiesfocussedcharacteristicsfunguseffectperipheralsystemlittleattentionpaidinteractsminireviewbrieflypaucitydataraisespertinentquestionsrespondthereaftermodelstechniquesadvancedtechnologiesusefulcarryinghigh-throughputReimaginingfutureAfricanhealth:PerspectivesCryptococcusNeuroimmuneresponsesNeuroinflammationSignallingpathways

Similar Articles

Cited By